Selective depletion of C-reactive protein by therapeutic apheresis (CRP apheresis) in Crohn's disease and ulcerative colitis

Selective depletion of C-reactive protein by therapeutic apheresis (CRP apheresis) in Crohn's disease and ulcerative colitis - CAMCRO1

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00015460

Enrollment

Registered

2018-08-31

Start date

2020-01-03

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K50 K51

Interventions

Group 1: Each study participant will initially receive 6 apheresis treatments, each lasting approximately 4-6 hours over a period of 3 weeks (twice a week). The following week is used to determine the

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Crohn's disease/ulcerative colitis with active but stable manifestations; Crohn's disease: CDAI 200 - 450 (Crohn's disease activity index); Ulcerative colitis: Mayo score 3-12; Crohn's disease manifestation: Colon and/or small intestine (endoscopic evidence); Ulcerative colitis manifestation: at least rectosigmoiditis; Stable therapy and medication within the previous 4 weeks

Exclusion criteria

Exclusion criteria: Age 38.0 °C), abscesses, blind fistulas, Known hypersensitivity to therapeutic apheresis, pregnancy or lactation, Participation in other interventional tests, Dialysis-liable renal failure

Design outcomes

Primary

Measure	Time frame
The plasma CRP concentration is determined before and after each apheresis (maximum 9 treatments) plus 2 control measurements each in the 4th and 8th week of treatment and 12 weeks after the start of treatment	—

Secondary

Measure	Time frame
Safety of CRP apheresis in the treatment of chronic inflammatory bowel disease (incidence of adverse effects of CRP apheresis), calprotectin concentration in stool, Crohn's disease activity index (CDAI)/Mayo score, Limberg score and „Short Inflammatory Bowel Disease Questionnaire“. The corresponding parameters are determined before the start of the apheresis treatments, as well as 4., 8. and 12. weeks after the start of treatment.	—

Measure

Time frame

Safety of CRP apheresis in the treatment of chronic inflammatory bowel disease (incidence of adverse effects of CRP apheresis), calprotectin concentration in stool, Crohn's disease activity index (CDAI)/Mayo score, Limberg score and „Short Inflammatory Bowel Disease Questionnaire“. The corresponding parameters are determined before the start of the apheresis treatments, as well as 4., 8. and 12. weeks after the start of treatment.

—

Countries

Germany

Contacts

Public ContactBurghard Thiesen

Pentracor GmbH

thiesen@pentracor.de+49 (0)3302 209 449 0

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026